70 studies found for:    integrins
Show Display Options
Rank Status Study
1 Terminated
Has Results
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
Condition: Advanced Non-Hematologic Malignancies
Intervention: Drug: PF-04605412
2 Completed A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
Conditions: High-grade Glioma;   Lung Cancer;   Head & Neck Cancer;   Sarcoma;   Melanoma
Intervention: Drug: [18F]AH-111585
3 Completed The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications
Condition: Genetic Polymorphism
Intervention:
4 Completed Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
Conditions: Melanoma;   Malignant Metastatic Melanoma
Interventions: Biological: MEDI--522;   Biological: Integrin + Dacarbazine
5 Withdrawn Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: monoclonal antibody anti-anb3 integrin;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: antibody therapy;   Procedure: biological response modifier therapy;   Procedure: growth factor antagonist therapy;   Procedure: monoclonal antibody therapy
6 Recruiting Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Muscular Dystrophy;   Congenital Muscular Dystrophy;   Fukutin-related Protein Gene;   Limb Girdle;   FKRP Gene;   Childhood Onset LGMD;   Adult Onset LGMD;   POMT1;   POMT2;   POMGnT1;   LARGE;   Alpha Dystroglycan;   Dystroglycanopathy;   Centronuclear;   Multiminicore;   Multicore;   Minicore;   Congenital Fiber Type Disproportion;   Myotubular;   Nemaline;   Congenital Myopathy;   Neuromuscular;   Rigid Spine;   Phenotype-Genotype Correlation;   Cough Assisted Device;   Neuromuscular Disease;   Respiratory Exacerbation;   Invasive Ventilation;   Chest Physiotherapy;   Congenital Myopathies;   Genetic Mutations;   Hypertrophic Cardiomyopathy;   Wheelchair Use;   Cataract;   Opthalmoplegia;   Ullrich Congenital Muscular Dystrophy;   Intermediate Collagen VI Myopathy;   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   MDC1A;   Merosin Deficient Congenital Muscular Dystrophy;   Congenital Muscular Dystrophy Undiagnosed;   Congenital Muscular Dystrophy Merosin Positive;   Walker Warburg Syndrome;   Muscle Eye Brain Disease;   Fukuyama;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   Laminopathy;   Lamin AC;   SEPN 1 Related Myopathies;   Bethlem Myopathy;   Dystroglycanopathies;   LGMD2K;   LGMD2I;   LGMD2L;   LGMD2N;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Disease Myopathy;   Congenital Myopathy Other;   Reducing Body Myopathy;   Sarcotubular Myopathy;   Spheroid Body Myopathy
Intervention:
7 Active, not recruiting Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis
Conditions: Hypertrophic Cardiomyopathy;   Acute Coronary Syndrome
Intervention: Radiation: 99mTc-NC100692
8 Active, not recruiting A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
Condition: Primary Focal Segmental Glomerulosclerosis
Intervention: Biological: Rituximab
9 Terminated Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
Conditions: Renal Cell Carcinoma;   Metastases
Intervention: Drug: Volociximab (anti-α5β1 integrin monoclonal antibody)
10 Completed A Pharmacokinetic (PK) Study of Tysabri at Steady State
Condition: Multiple Sclerosis
Intervention: Drug: natalizumab
11 Recruiting 68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
Condition: Glioma
Intervention: Drug: 68Ga-BNOTA-PRGD2
12 Not yet recruiting RGD-PET-CT in Cancer Angiogenesis
Condition: Carcinoma, Renal Cell
Intervention: Drug: 18F-RGD-PET-CT and perfusion CT scans on 3 occasions
13 Active, not recruiting Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Condition: Squamous Cell Cancer
Interventions: Drug: Cilengitide 2000 mg once weekly;   Drug: Cilengitide 2000 mg twice weekly;   Drug: Cetuximab;   Drug: 5-fluorouracil (5-FU);   Drug: Cisplatin
14 Recruiting PK and PD Study of Natalizumab in Pediatric Subjects With RRMS
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: Natalizumab
15 Recruiting Stem Cell Transplant for Epidermolysis Bullosa
Condition: Epidermolysis Bullosa
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Hematopoietic stem cell transplant;   Procedure: Mesenchymal stem cell transplant;   Radiation: Total body irradiation
16 Not yet recruiting Angiogenesis and Fibrosis in Myocardial Infarction
Conditions: Myocardial Infarction;   Fibrosis;   Neovascularization, Pathologic
Interventions: Procedure: Cardiac MRI scan;   Radiation: CT-PET scan;   Radiation: CT-coronary angiogram
17 Recruiting 18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
18 Completed
Has Results
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Docetaxel;   Drug: Prednisone;   Biological: Intetumumab;   Drug: Placebo
19 Completed
Has Results
A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
Condition: Melanoma
Interventions: Drug: Intetumumab;   Drug: Dacarbazine;   Drug: Placebo
20 Recruiting [18F]Fluciclatide PET Imaging of Pazopanib Response
Condition: Kidney Neoplasm
Intervention: Drug: 18F-Fluciclatide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years